Next Generation Transcranial Magnetic Stimulation
Image credit: the inventors
A smaller, more affordable device to increase access to Transcranial Magnetic Stimulation.
About the Technology
Transcranial Magnetic Stimulation (TMS) is an FDA-approved therapy for treatment-resistant depression, a condition affecting millions of people in the U.S. But TMS relies on expensive, bulky equipment, leaving the therapy out of reach of many clinicians and patients.
Our innovation is a compact, portable, cost-effective TMS device that will dramatically expand access to brain-stimulation therapy. Key improvements like high voltage power system miniaturization and the elimination of liquid cooling mean our TMS device no longer requires special power supplies, and can be easily implemented in psychiatrist’s offices and rural clinics.
Our device builds on groundbreaking TMS protocols developed at Stanford which have proven effective for a majority of patients with serious depression. This therapy already has CPT codes, and, with our new device, addresses a market of more than 8 million depression patients in the U.S. not currently able to access TMS therapy.
The HIT Fund will support customer discovery and validation of product-market fit, and help us find potential partnership opportunities and an optimal business model.
Team Members
Juan Rivas-Davila, DSc
Director of Stanford University Power Electronics Research Lab, Associate Professor
Electrical Engineering
Irakli Kaloiani, MD
Staff Scientist
Stanford Brain Stimulation Lab
